Aspirin Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Aspirin Availability in 2026

Aspirin (acetylsalicylic acid) remains one of the most prescribed and recommended medications in cardiovascular medicine, rheumatology, and primary care. As a provider, keeping up with availability, cost, and patient access issues ensures continuity of care — especially for patients on chronic antiplatelet therapy.

This briefing covers the current supply picture, prescribing considerations, and actionable tools to support your patients.

Current Shortage Status and Timeline

As of March 2026, Aspirin is not listed on the FDA's drug shortage database. Unlike medications such as amphetamine mixed salts or GLP-1 receptor agonists, Aspirin has not experienced a formal nationwide shortage.

However, providers should be aware of formulation-specific availability fluctuations:

• Generic Aspirin 81 mg and 325 mg tablets — widely available from multiple manufacturers; no significant supply concerns
• Vazalore (PL-ASA) — as a single-source branded product, periodic supply variability has been reported. Vazalore uses a phospholipid-aspirin complex designed to reduce GI injury.
• Durlaza (extended-release Aspirin) — limited availability; this formulation has faced intermittent distribution challenges
• Aspirin IV formulations — primarily used in acute care settings; availability may vary by hospital supply contracts

The overall picture: the active pharmaceutical ingredient (ASA) is abundant, but niche formulations may require workarounds.

Prescribing Implications

For the majority of clinical scenarios, Aspirin access is straightforward. Key prescribing considerations in the current environment:

Cardiovascular Prevention

• Low-dose Aspirin (81 mg daily) remains standard for secondary prevention of cardiovascular events. The 2019 ACC/AHA guidelines narrowed primary prevention recommendations, but secondary prevention indications are unchanged.
• For patients with documented atherosclerotic cardiovascular disease (ASCVD), dual antiplatelet therapy (DAPT) with Aspirin plus Clopidogrel or Ticagrelor may be indicated post-ACS or post-PCI.
• If a patient reports difficulty obtaining their specific Aspirin product, generic substitution across formulations is generally appropriate — though enteric-coated vs. immediate-release may affect patient adherence and GI tolerability.

Pain and Inflammation

• For musculoskeletal pain, Aspirin 325-650 mg q4-6h remains an option but is less commonly first-line compared to Ibuprofen or Naproxen due to GI risk profile at analgesic doses.
• In rheumatic conditions requiring high-dose salicylate therapy (3.6-5.4 g/day), monitoring serum salicylate levels is essential.

Special Populations

• Pediatrics: Aspirin is contraindicated in children and teenagers with viral illness due to Reye syndrome risk. Exception: Kawasaki disease treatment under specialist guidance.
• Pregnancy: Low-dose Aspirin (81 mg) is recommended by ACOG for preeclampsia prevention in high-risk pregnancies (starting at 12-28 weeks). Avoid in the third trimester.
• Elderly: Increased GI bleeding risk. Consider gastroprotection (PPI co-therapy) for patients on chronic Aspirin, especially if on concurrent anticoagulants or corticosteroids.

The Availability Picture

Aspirin is manufactured by numerous companies and is available as:

• OTC in all 50 states without a prescription
• Multiple generic manufacturers ensure redundant supply
• Available in tablet, chewable, enteric-coated, suppository, and IV formulations

The primary access challenge patients face is formulation-specific rather than drug-level. If a patient calls your office reporting they can't find Aspirin, the issue is almost certainly their specific brand or coating preference, not the medication itself.

Cost and Access

Aspirin remains one of the most affordable medications available:

• Generic OTC pricing: $2-$12 for a 90-day supply of 81 mg tablets
• Prescription Aspirin: Rarely needed; most patients purchase OTC
• Discount programs: GoodRx coupons bring the price as low as $6; SingleCare offers similar savings
• Insurance: Generally not covered as an OTC product, but FSA/HSA eligible
• Vazalore (brand): $15-$30+ per month; manufacturer coupons available at vazalore.com

Cost is rarely a barrier for generic Aspirin. For patients who struggle with any medication costs, our provider guide to helping patients save on Aspirin offers additional resources.

Tools and Resources for Your Practice

Medfinder for Providers offers tools to help your patients locate medications in stock at nearby pharmacies. Instead of fielding calls about pharmacy availability, you can direct patients to check Medfinder before calling your office.

Additional resources:

• FDA Drug Shortage Database: accessdata.fda.gov — check real-time shortage status
• ASHP Drug Shortage Resource Center: Updated shortage information and clinical guidance
• Medfinder Provider Portal: medfinder.com/providers — help patients find medications in stock

Looking Ahead

Aspirin's supply outlook for 2026 and beyond is positive. Key factors supporting continued availability:

• Multiple generic manufacturers with established production capacity
• Stable raw material (ASA) supply globally
• Strong OTC distribution through pharmacies, retailers, and online channels
• No regulatory changes anticipated that would affect supply

The main development to watch is evolving guidelines on primary prevention. As recommendations shift, demand patterns may change — but this is unlikely to cause supply disruptions for a drug as widely manufactured as Aspirin.

Final Thoughts

Aspirin availability is strong in 2026. For providers, the action items are straightforward: reassure patients that supply is stable, assist with formulation switches when needed, and leverage tools like Medfinder to streamline pharmacy access. For patients struggling with specific formulations, a quick consultation on equivalent options is usually all that's needed to keep them on track.

For the patient-facing version of this update, see our Aspirin shortage update for patients.